King's College London

Research portal

Exploring the link between GBA1 mutations and Dementia with Lewy bodies, A mini-review

Research output: Contribution to journalReview articlepeer-review

Sinead Gaubert, Claire Hourregue, François Mouton-Liger, Périne Millot, Mélanie Franco, Elodie Amar-Bouaziz, Dag Aarsland, Jacques Hugon, Claire Paquet

Original languageEnglish
Article number104856
JournalNeuroscience and Biobehavioral Reviews
Volume141
Early online date13 Sep 2022
DOIs
Accepted/In press2 Sep 2022
E-pub ahead of print13 Sep 2022
PublishedOct 2022

Bibliographical note

Publisher Copyright: © 2022

King's Authors

Abstract

Importance: Dementia with Lewy bodies (DLB) is a neurodegenerative disease linked to abnormal accumulation of phosphorylated α-synuclein. GBA1 is the gene encoding the lysosomal enzyme glucocerebrosidase (GCase), whose mutations are a risk factor of DLB. Objective: To report all available data exploring the association between GBA1 mutations and DLB. Evidence Review: All publications focused on GCase and DLB in humans between 2003 and 2022 were identified on PubMed, Cochrane and ClinicalTrials.gov. Findings: 29 studies were included and confirmed the strong association between GBA1 mutations and DLB (Odds Ratio [OR]: 8.28). GBA1 mutation carriers presented a more malignant phenotype, with earlier symptom onset, more severe motor and cognitive dysfunctions, more visual hallucinations and rapid eye movement sleep disorder. GBA1 mutations were associated with “purer” neuropathological DLB. No therapeutic recommendations exist and clinical trials targeting GCase are just starting in DLB patients. Conclusions and Relevance: This review reports a link between GBA1 mutations and the DLB phenotype with limited evidence due to the small number of studies.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454